InvestSMART

Firebrick Pharma Limited (ASX:FRE)

ALERT: Price-sensitive ASX Announcement for FRE
Current share price for FRE : $0.028 -0.034 (-54.84%)+
Announcement
Release
23 Oct 2025 8:22AM
Price at Release
$0.062
Full Release
download
Summary
Firebrick Pharma Limited's September 2025 Quarterly Activity Report highlights a 9% increase in operating cash costs due to production-related expenses and regulatory filings, partially offset by reduced staff and marketing costs. The company secured $1.4 million from a placement, enhancing its funding capacity for expanding Nasodine's market reach in the US and Southeast Asia, and developing new products for FY2026. The cash reserves at the quarter's end stood at $1.94 million, projected to support operations for over a year. A notable board change included the appointment of Rick Legleiter and the passing of Dr. Phyllis Gardner.
Key Points
  • 9% increase in operating cash costs.
  • Placement of $1.4 million secured.
  • Expansion of Nasodine in US and Southeast Asian markets.
  • Cash reserves at $1.94 million at quarter's end.
  • Projected 12 months of operational funding.
  • Appointment of Rick Legleiter as non-executive director.
  • Passing of non-executive director Dr. Phyllis Gardner.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.